High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Ghia, Emanuela M. [1 ]
Rassenti, Laura Z. [1 ]
Choi, Michael Y. [1 ]
Chu, Elvin [1 ]
Widhopf, George F., II [1 ]
Kipps, Thomas J. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131426
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
476
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
    Tausch, Eugen
    Close, William
    Dolnik, Anna
    Bloehdorn, Johannes
    Chyla, Brenda
    Bullinger, Lars
    Doehner, Hartmut
    Mertens, Daniel
    Stilgenbauer, Stephan
    HAEMATOLOGICA, 2019, 104 (09)
  • [2] Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia.
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Choi, Michael Y.
    Quijada-Alamo, Miguel
    Chu, Elvin
    Widhopf, George F.
    Kipps, Thomas J.
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04): : 311 - 322
  • [4] Venetoclax targets BCL2 in chronic lymphocytic leukaemia
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (01): : E11 - E11
  • [5] Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia
    Tam, Constantine S.
    Seymour, John F.
    Roberts, Andrew W.
    SEMINARS IN ONCOLOGY, 2016, 43 (02) : 274 - 279
  • [6] Potential of BCL2 as a target for chronic lymphocytic leukemia treatment
    Moia, Riccardo
    Diop, Fary
    Favini, Chiara
    Kodipad, Ahad Ahmed
    Gaidano, Gianluca
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) : 391 - 402
  • [7] Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax
    Blombery, Piers
    Thompson, Ella
    Tamia Nguyen
    Chen, Xiangting
    McBean, Michelle
    Birkinshaw, Richard W.
    Czabotar, Peter E.
    Thijssen, Rachel
    Anderson, Mary Ann
    Seymour, John F.
    Westerman, David Alan
    Huang, David C. S.
    Roberts, Andrew W.
    BLOOD, 2019, 134
  • [8] Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
    Kotmayer, Lili
    Laszlo, Tamas
    Mikala, Gabor
    Kiss, Richard
    Levay, Luca
    Hegyi, Lajos Laszlo
    Grof, Stefania
    Nagy, Tibor
    Barna, Gabor
    Farkas, Peter
    Weisinger, Julia
    Nagy, Zsolt
    Balogh, Alexandra
    Masszi, Tamas
    Demeter, Judit
    Sulak, Adrienn
    Kohl, Zoltan
    Alizadeh, Hussain
    Egyed, Miklos
    Pettendi, Piroska
    Gergely, Lajos
    Plander, Mark
    Pauker, Zsolt
    Masszi, Andras
    Matolcsy, Andras
    Szasz, Robert
    Bodor, Csaba
    Alpar, Donat
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [9] Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
    Blombery, Piers
    Thompson, Ella R.
    Tamia Nguyen
    Birkinshaw, Richard W.
    Gong, Jia-Nan
    Chen, Xiangting
    McBean, Michelle
    Thijssen, Rachel
    Conway, Thomas
    Anderson, Mary Ann
    Seymour, John F.
    Westerman, David A.
    Czabotar, Peter E.
    Huang, David C. S.
    Roberts, Andrew W.
    BLOOD, 2020, 135 (10) : 773 - +
  • [10] Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
    Fevzi F. Yalniz
    William G. Wierda
    Drugs, 2019, 79 : 1287 - 1304
12345